|
Volume 16, Issue 3, March 2009, in PDF
|
   |
Article: 593
Pharma Consolidation Slows CRO Market in Short Term
Pharmaceutical companies have responded to financial and market pressures by aggressively pursuing mergers and acquisitions, with the biggest being Pfizer’s planned acquisition of Wyeth. More consolidation activity is expected.
Article: 594
CROs’ Oncology Focus Grows
Oncology is one of the key disease areas expected to dominate drug discovery and development well into the future, and CROs with strong oncology franchises should benefit from that development trend.
Article: 595
European CROs Off to a Running Start in 2009
Two planned acquisitions and one merger already this year indicate that European contract research organizations (CROs) in 2009 are bulking up, as market share continues to shift toward global CROs.
Article: 596
Eye On:Alzheimer’s Disease
Alzheimer’s disease (AD) is the leading cause of dementia, or chronic, progressive loss of brain function, affecting about half to nearly three quarters of all people with dementia. This degenerative disease, characterized by irreversible, progressive destruction of brain cells and by amyloid plaques and neurofibrillary tangles, gets its name from Aloïs Alzheimer, the German neurologist who first described the condition in 1907.
Price: $59.00
|
